Research progress of Gd-EOB-DTPA enhanced MRI in evaluating liver function

Share this content in WeChat

• Review •

SHAO Jia HE Yexin

Cite this article as: Shao J, He YX. Research progress of Gd-EOB-DTPA enhanced MRI in evaluating liver function. Chin J Magn Reson Imaging, 2020, 11(11): 1056-1058. DOI:10.12015/issn.1674-8034.2020.11.023.

Abstract

[Abstract] Magnetic resonance imaging plays an important role in the detection of liver diseases. Gadolinium-ethoxybenzyl-diethylenetriamine pentaacetic acid (Gd-EOB-DTPA) is one of the commonly used liver-specific contrast agents in clinical practice. It is not only of great significance in the detection of focal lesions, but also of potential application value in the assessment of diffuse liver damage. Quantitative evaluation of liver function in different segments based on anatomical information is more important for the selection of appropriate treatment for patients with chronic liver disease and liver cancer. In recent years, Gd-EOB-DTPA-enhanced magnetic resonance imaging has become more and more widely used in clinical practice, and its methods for assessing liver function mainly include measurement of relaxation time before and after enhanced, changes in liver parenchymal signal intensity, the biliary tract signal intensity and bile duct imaging time and measurement of contrast agent in bile duct. This article reviews the related research on the diagnostic value of Gd-EOB-DTPA enhanced magnetic resonance imaging for liver function.

[Keywords] liver function tests；paramagnetic contrast mediums；magnetic resonance imaging

Contributor Information

SHAO Jia Shanxi Medical University, Taiyuan 030001, China

HE Yexin^* Department of MRI, Affiliated People's Hospital of Shanxi Medical University, Taiyuan 030012, China

*Correspondence to: He YX, E-mail: heyexinty2000@sina.com

Conflicts of interest None.

Publication Information

Received 2020-03-21

Accepted 2020-07-25

DOI: 10.12015/issn.1674-8034.2020.11.023

Text

References

[1]

Ribero D, Amisano M, Bertuzzo F, et al. Measured versus estimated total liver volume to preoperatively assess the adequacy of the future liver remnant. Which method should we use? Ann Surg, 2013, 258(5): 801-807. DOI: 10.1097/sla.0000000000000213

[2]

Guglielmi A, Ruzzenente A, Conci S, et al. How much remnant is enough in liver resection? Dig Surg, 2012, 29(1): 6-17. DOI: 10.1159/000335713

[3]

Ray S, Mehta NN, Golhar A, et al. Post hepatectomy liver failure: a comprehensive review of current concepts and controversies. Ann Med Surg (Lond), 2018, 34: 4-10. DOI: 10.1016/j.amsu.2018.08.012

[4]

Ippolitoc D, Famularo S, Giania A, et al. Estimating liver function in a large cirrhotic cohort: signal intensity of gadolinium-ethoxybenzyl-diethylenetriamine penta-aceticacid-enhanced MRI. Dig Liver Di, 2019, 51(10): 1438-1445. DOI: 10.1016/j.dld.2019.04.009

[5]

Hinrichs H, Hinrichs JB, Gutberlet M, et al. Functional gadoxetate disodium-enhanced MRI in patients with primary sclerosing cholangitis (PSC). Eur Radiol, 2016, 26(4): 1116-1124. DOI: 10.1007/s00330-015-3913-y

[6]

Yoon JH, Lee JM, Paek M, et al. Quantitative assessment of hepatic function: modified look-locker inversion recovery (MOLLI) sequence for T1 mapping on Gd-EOB-DTPA-enhanced liver MR imaging. Eur Radiol, 2016, 26(6): 1775-1782. DOI: 10.1007/s00330-015-3394-7

[7]

Yoon JH, Lee JM, Kim E, et al. Quantitative liver function analysis: volumetric T1 mapping with fast multisection B1 inhomogeneity correction in hepatocyte-specific contrast-enhanced liver MR imaging. Radiology, 2017, 282(2): 408-417. DOI: 10.1148/radio.2016152800

[8]

Chang CC, Huang HC, Liu KL, et al. Clinical feasibility of Gd-EOB-DTPA-enhanced MR imaging for assessing liver function: validation with ICG tests and parenchymal cell volume. Clin Imaging, 2016, 40(4): 797-800. DOI: 10.1016/j.clinimag.2016.03.003

[9]

Yoon JH, Choi JI, Jeong YY, et al. Pre-treatment estimation of future remnant liver function using gadoxetic acid MRI in patients with HCC. J Hepatol, 2016, 65(6): 1155-1162. DOI: 10.1016/j.jhep.2016.07.024

[10]

Van Beers BE, Catherine M. Pastor HK. Hussain. primovist, eovist: what to expect? J Hepatol, 2012, 57(2): 421-429. DOI: 10.1016/j.jhep.2012.01.031

[11]

Jia J, Puls D, Oswald S, et al. Characterization of the intestinal and hepatic uptake/efflux transport of the magenetic resonance imaging contrast agent Gadolinium-ethoxybenzyl-diethylenetriamine pentaacetic acid. Invest Radiol, 2014, 49(2): 78-86. DOI: 10.1097/rli.0b013e3182a70043

[12]

Kobi M, Paroder V, Flusberg M, et al. Limitations of GD-EOB-DTPA-enhanced MRI: can clinical parameters predict suboptimal hep- atobiliary phase? Clin Radiol, 2017, 72(1): 55-62. DOI: 10.1016/j.crad.2016.10.004

[13]

Ding Y, Rao SX, Meng T, at al. Usefulness of T1 mapping on Gd-EOB-DTPA-enhanced MR imaging in assessment of non-alcoholic fatty liver disease. Eur Radiol, 2014, 24(4): 959-996. DOI: 10.1007/s00330-014-3096-y

[14]

Pan S, Wang XQ, Guo QY. Quantitative assessment of hepatic fibrosis in chronic hepatitis B and C: T1 mapping on Gd-EOB-DTPA-enhanced liver magnetic resonance imaging. World J Gastroenterol, 2018, 24(18): 2024-2035. DOI: 10.3748/wjg.v24.i18.2024

[15]

邱天，张占卿，陈伟波，等.钆塞酸二钠增强MRT1 mapping成像定量评估乙型肝炎肝纤维化的价值．中华放射学杂志, 2019, 53(12): 1081-1085. DOI: 10.3760/cma.j.issn.1005-1201.2019.12.011

[16]

Gschwend S, Ebert W, Schultze-Mosgau M, et al. Pharmacokinetics and imaging properties of Gd-EOB-DTPA in patients with hepatic and renal impairment. Invest Radiol, 2011, 46(9): 556-566. DOI: 10.1097/rli.0b013e31821a218a

[17]

Ringe KI, Husarik DB, Sirlin CB, et al. Gadoxetate disodium-enhanced MRI of the liver: part 1, protocol optimization and lesion appearance in the noncirrhotic liver. AJR Am J Roentgenol, 2010, 195(1): 13-28. DOI: 10.2214/ajr.10.4392

[18]

Verloh N, Haimerl M, Rennert J, et al. Impact of liver cirrhosis on liver enhancement at Gd-EOB-DTPA enhanced MRI at 3 Tesla. Eur J Radiol, 2013, 82(10): 1710-1715. DOI: 10.1016/j.ejtad.2013.05.033

[19]

Haimerl M, Verloh N, Zeman F, et al. Gd-EOB-DTPA-enhanced MRI for evaluation of liver function: comparison between signal intensity-based indices and T1 relaxometry. Sci Rep, 2017, 7(1): 43347. DOI: 10.1038/srep43347

[20]

Zhang WG, Wang X, Miao YH, et al. Liver function correlates with liver-to-portal vein contrast ratio during the hepatobiliary phase with Gd-EOB-DTPA-enhanced MR at 3 Tesla. Abdom Radiol, 2018, 43(9): 2262-2269. DOI: 10.1007/s00261-018-1462-y

[21]

Ippolito D, Pecorelli A, Famularo S, et al. Assessing liver function: diagnostic efficacy of parenchymal enhancement and liver volume ratio of Gd-EOB-DTPA-enhanced MRI study during interstitial and hepatobiliary phase. Abdom Radiol, 2019, 44(4): 1340-1349. DOI: 10.1007/s00261-018-1812-9

[22]

Katsube T, Okada M, Kumano S, et al. Estimation of liver function using T1 mapping on Gd-EOB-DTPA-enhanced magnetic resonance imaging. Invest Radiol, 2011, 46(4): 277-283. DOI: 10.1097/rli.0b013e318200f67d

[23]

蒋宇，邱维加，李迅，等.钆塞酸二钠增强MR T1 mapping结合标准肝脏体积率评估肝功能的价值．中华放射学杂志, 2019, 53(12): 1076-1080. DOI: 10.3760/cma.j.issn.1005-1201.2019.12.010

[24]

Zhou ZP, Long LL, Qiu WJ, et al. Evaluating segmental liver function using T1 mapping on Gd-EOB-DTPA-enhanced MRI with a 3.0 Tesla. BMC Medical Imaging, 2017, 17(1): 20. DOI: 10.1186/s12880-017-0192-x

[25]

Yoon JH, Lee JM, Kang HJ, et al. Quantitative assessment of liver function by using gadoxetic acid-enhanced MRI: hepatocyte uptake ratio. Radiology, 2019, 290(1): 125-133. DOI: 10.1148/radiol.2018180753

[26]

Yoo H, Lee JM, Yoon JH, et al. T2* mapping from multi-echo dixon sequence on gadoxetic acid-enhanced magnetic resonance imaging for the hepatic fat quantification: can it be used for hepatic function assessment? Korean J Radiol, 2017, 18(4): 682-690. DOI: 10.3348/kjr.2017.18.4.682

[27]

Verloh N, Utpatel K, Zeman F, et al. Diagnostic performance of Gd-EOB-DTPA-enhanced MRI for evaluation of liver dysfunction: a multivariable analysis of 3 T MRI sequences. Oncotarget, 2018, 9(91): 36371-36378

[28]

Ringe KI, Husarik DB, Gupta RT, et al. Hepatobiliary transit times of gadoxetate disodium (Primovist®) for protocol optimization of comprehensive MR imaging of the biliary system--what is normal? Eur J Radiol, 2011, 79(2): 201-205. DOI: 10.1016/j.ejrad.2010.03.008

[29]

Tschirch FT, Struwe A, Petrowsky H, et al. Contrast-enhanced MR cholangiography with Gd-EOB-DTPA in patients with liver cirrhosis: visualization of the biliary ducts in comparison with patients with normal liver parenchyma. Eur Radiol, 2008, 18(8): 1577-1586. DOI: 10.1007/s00330-008-0929-6

[30]

Noda BY, Goshima S, Kajita K, et al. Biliary tract enhancement in gadoxetic acid-enhanced MRI correlates with liver function biomarkers. Eur J Radiol, 2016, 85(11): 2001-2007. DOI: 10.1016/j.ejrad.2016.09.003

PREV Application of resting state fMRI in the study of the obstructive sleep apnea-hypopnea syndrome

NEXT Progress in the application of multimodal imaging technique in hepatic cystic hydatidosis

LINK

Tel & Fax: +8610-67113815 E-mail: editor@cjmri.cn